Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 5/20 | 0.60 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL23702350 | 1.00 | — | — | |
| Bicarbonate SCHEMBL23525300 | 0.94 | — | — | |
| Bicarbonate SCHEMBL28420909 | 0.94 | CA4 (0.67) | CA4FAHD1MEN1LDHABLM | |
| Bicarbonate SCHEMBL2351948 | 0.94 | CA4 (0.67) | CA4FAHD1MEN1LDHABLM | |
| Bicarbonate SCHEMBL1332143 | 0.94 | — | — | |
| Bicarbonate SCHEMBL1930 | 0.94 | — | — | |
| Bicarbonate SCHEMBL1697622 | 0.94 | CA4 (0.50) | CA4FAHD1MEN1LDHABLM | |
| Bicarbonate SCHEMBL852 | 0.94 | — | — | |
| Bicarbonate SCHEMBL2275798 | 0.94 | CA4 (0.67) | CA4FAHD1MEN1LDHABLM | |
| Bicarbonate SCHEMBL2560104 | 0.89 | CA4 (0.50) | CA4FAHD1MEN1LDHABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834430-B2 | Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-12-05 | — | — | US | disclosed |
| CN-113683629-B | Substituted heteroaryl compounds, compositions and uses thereof | 北京范恩柯尔生物科技有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20210130317-A1 | Compounds Useful as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-05-06 | — | — | US | disclosed |
| EP-3681878-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE | Agency for Science, Technology and Research (SG) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019054944-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-21 | — | — | WO | disclosed |
| EP-3209669-A1 | SUBSTITUTED 1,2,3-TRIAZOL-1-YL-METHYL-2,3-DIHYDRO-2-METHYL-6-NITROIMIDAZO[2,1-B]OXAZOLES AS ANTI-MYCOBACTERIAL AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2017-08-30 | — | — | EP | disclosed |
| US-20170008886-A1 | A PROCESS FOR THE PREPARATION OF APIXABAN AND ITS INTERMEDIATES | WANBURY LTD. (IN) | 2017-01-12 | — | — | US | disclosed |
| EP-3097100-A2 | A PROCESS FOR THE PREPARATION OF APIXABAN AND ITS INTERMEDIATES | Wanbury Limited (IN) | 2016-11-30 | — | — | EP | disclosed |
| WO-2015111073-A2 | A PROCESS FOR THE PREPARATION OF APIXABAN AND ITS INTERMEDIATES | WANBURY LTD. (IN) | 2015-07-30 | — | — | WO | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| CN-1518534-A | Copper-catalyzed carbon-heteroatom and carbon-carbon bond formation | 麻省理工学院 | 2004-08-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130317-A1 | Compounds Useful as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase | ICMT, INMT, BHMT | CA4 1764/4885FAHD1 452/4885MEN1 200/4885 |
| US-11834430-B2 | Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase | ICMT, INMT, BHMT | CA4 1764/4885FAHD1 452/4885MEN1 200/4885 |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | GPI, ERG28, MAN2A1 | CA4 3578/4885FAHD1 4883/4885MEN1 2913/4885 |
| US-20170008886-A1 | A PROCESS FOR THE PREPARATION OF APIXABAN AND ITS INTERMEDIATES | VKORC1, VKORC1L1, F11 | CA4 679/4885FAHD1 2155/4885MEN1 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.